Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.
2.

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.

Salaj P, Penka M, Smejkal P, Geierova V, Ovesná P, Brabec P, Cetkovsky P, Kubes R, Mesterton J, Lindgren P.

Thromb Res. 2012 May;129(5):e233-7. doi: 10.1016/j.thromres.2012.02.005. Epub 2012 Mar 2.

PMID:
22386136
3.

Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.

You CW, Lee SY, Park SK.

Haemophilia. 2009 Jan;15(1):217-26. doi: 10.1111/j.1365-2516.2008.01862.x. Epub 2008 Aug 25.

PMID:
18754800
4.

Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.

Steen Carlsson K, Astermark J, Donfield S, Berntorp E.

Thromb Haemost. 2008 Jun;99(6):1060-7. doi: 10.1160/TH07-11-0698.

PMID:
18521509
5.
6.

Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.

Hay JW, Zhou ZY.

Haemophilia. 2011 Sep;17(5):e969-74. doi: 10.1111/j.1365-2516.2011.02589.x. Epub 2011 Jun 7.

PMID:
21649802
7.

Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.

Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM.

Haemophilia. 2009 Sep;15(5):1083-9. doi: 10.1111/j.1365-2516.2009.02038.x. Epub 2009 Apr 27. Review.

PMID:
19456876
8.
9.

Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.

Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.

Haemophilia. 2015 May;21(3):320-9. doi: 10.1111/hae.12681. Epub 2015 Apr 9.

PMID:
25855214
10.

Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.

Nakamura S, Morimoto A, Oh Y, Hayase T, Kashii Y, Gunji Y, Momoi MY.

Blood Coagul Fibrinolysis. 2012 Apr;23(3):235-7. doi: 10.1097/MBC.0b013e32834fb582.

PMID:
22322137
11.

A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.

Knight C, Danø AM, Kennedy-Martin T.

Haemophilia. 2009 Mar;15(2):405-19. doi: 10.1111/j.1365-2516.2008.01969.x. Epub 2009 Feb 1. Review.

PMID:
19187191
12.

Prevention of haemophilic arthropathy in haemophilic children with inhibitors.

Rodriguez-Merchan EC.

Haemophilia. 2008 Nov;14 Suppl 6:1-3. doi: 10.1111/j.1365-2516.2008.01881.x.

PMID:
19134025
13.

Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.

Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA.

Haemophilia. 2010 May;16(3):510-7. doi: 10.1111/j.1365-2516.2009.02164.x. Epub 2009 Dec 29. Erratum in: Haemophilia. 2010 May;16(3):567.

PMID:
20050927
14.

Experiences in the prevention of arthropathy in haemophila patients with inhibitors.

Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F.

Haemophilia. 2008 Nov;14 Suppl 6:28-35. doi: 10.1111/j.1365-2516.2008.01887.x. Review.

PMID:
19134031
15.

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.

Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF.

Curr Med Res Opin. 2006 Jan;22(1):23-31.

PMID:
16393427
16.

Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.

Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE.

Haemophilia. 2009 May;15(3):727-32. doi: 10.1111/j.1365-2516.2009.02017.x.

PMID:
19320748
17.

Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.

Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP.

Haemophilia. 2011 Nov;17(6):910-9. doi: 10.1111/j.1365-2516.2011.02504.x. Epub 2011 Feb 22. Review.

PMID:
21342367
18.

Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.

Hay JW, Zhou ZY.

Haemophilia. 2010 Mar;16(2):366-8; discussion 369-71. doi: 10.1111/j.1365-2516.2009.02117.x. Epub 2009 Oct 6. No abstract available.

PMID:
19811544
19.

Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.

Hay JW, Zhou ZY.

J Med Econ. 2011;14(4):516-25. doi: 10.3111/13696998.2011.595462. Epub 2011 Jun 23. Review.

PMID:
21699366
20.

Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.

Balkan C, Karapinar D, Aydogdu S, Ozcan C, Ay Y, Akin M, Kavakli K.

Haemophilia. 2010 Nov;16(6):902-9. doi: 10.1111/j.1365-2516.2010.02329.x.

PMID:
20518817
Items per page

Supplemental Content

Write to the Help Desk